Homelife sciences

life sciences

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer

December 23, 2022

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2022 Financial Results and Provides Business Update

December 22, 2022

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

December 22, 2022

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

Aquestive Therapeutics Announces Completion of FDA End-of-Phase 2 Meeting For AQST-109 (epinephrine sublingual film)

December 22, 2022

$Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia$

Affimed Announces Approval of Clinical Trial Application in France for a Phase 1 Study of AFM28 in Relapsed/Refractory Acute Myeloid Leukemia

December 22, 2022

CLASS ACTION UPDATE for EIGR, VERU and NBEVQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for EIGR, VERU and NBEVQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

December 21, 2022

Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

Achieve Life Sciences Announces Patent Granted by USPTO for New Cytisinicline Formulation

December 21, 2022

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ:EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ:EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)

December 21, 2022

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

Celyad Oncology provides an update on its strategic business model, continuing to focus on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property

December 21, 2022

CLASS ACTION UPDATE for FRSH, SEDG and EIGR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

CLASS ACTION UPDATE for FRSH, SEDG and EIGR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

December 20, 2022

« 1 … 6 7 8 9 10 … 557 »